Hartalega - 1QFY19 - Results Review

Date: 08/08/2018

Source  :  BIMB
Stock  :  HARTA       Price Target  :  5.50      |      Price Call  :  HOLD
        Last Price  :  5.30      |      Upside/Downside  :  +0.20 (3.77%)

  • Hartalega 1QFY19 recorded a quarterly all-time high revenue and PATMI growing by 17.5% and 29.6% yoy respectively.
  • The strong performance was due to robust demand for nitrile gloves leading to higher sales volume (+20.5% yoy, +6.4% qoq) supported by increased production capacity and improved operating cost efficiency.
  • Overall, results were in-line with our full year forecast at 24.7%.
  • Maintain Hold with unchanged TP of RM5.50 based on PER 34x applied on CY19 EPS for now, pending management meeting.

All-time high quarterly performance

Hartalega posted an impressive 1QFY19 results, as revenue and PATMI grew to RM706.4m (+17.5%) and RM124.9m (+29.6%) yoy respectively. This was driven by a 20.5% yoy sales volume growth, mainly due to strong demand for nitrile gloves supported by NGC plant running at higher utilization rate of 92% (vs 1QFY18:91%). Additionally, lower nitrile raw material cost yoy and improvements in operating efficiencies have resulted in higher EBITDA margin of 24.5% (+1.5ppts yoy).

Improved qoq performance

Revenue increased by 14.5% qoq mainly due to increase sales volume (+6.4%) and higher ASP (+8%) resulting from higher natural gas price cost pass through time lag. Nevertheless, bottom line grew slower at 7.5% impacted by margin compression of 1.1ppts which we believe was due to recent hike in nitrile raw material prices.

Outlook remains positive moving forward

We expect Hartalega outlook to remain strong on the back of robust global demand for nitrile gloves (60% Malaysia export), as well as its strategic expansion plans and product innovation. Hartalega’s NGC is on track to meet rising demand with the commissioning of Plant 5 (4.7bn pcs, +c.14%). The initial line is to start in early Aug with targeted 2 new lines each month. Moving forward, Plant 6 and 7 are targeted to commence production in 1HCY19 and 2HCY19 respectively, bringing additional capacity of 7.3bn pcs pa. Additionally, the group have launched its antimicrobial gloves (AMG) in Europe on 31st May 2018 and is working on FDA approval to enter the US market with competitive pricing to ensure better take-up rate.

Maintain Hold with TP of RM5.50

We estimate Hartalega FY19 earnings to grow by 15% yoy, supported by resilient demand, lower ringgit against USD and overall cost efficiency. We maintain our earnings forecast at this juncture pending management meeting next week. Maintain Hold with TP unchanged at RM5.50 based on 34x PER (+1SD 3-years historical mean) on CY19 EPS. We still like Hartalega for its leadership position in the nitrile gloves, strong operating efficiencies and higher margin compare to its peers.

Source: BIMB Securities Research - 8 Aug 2018

Share this
Labels: HARTA

Related Stocks

Chart Stock Name Last Change Volume 
HARTA 5.30 +0.05 (0.95%) 12,923,500 

  Be the first to like this.


402  326  492  672 

Top 10 Active Counters
 ARMADA 0.22+0.06 
 SAPNRG 0.285-0.005 
 SUMATEC 0.005-0.01 
 MYEG 1.01-0.06 
 BARAKAH 0.08+0.02 
 NEXGRAM 0.020.00 
 IRIS 0.15+0.005 
 XINGHE 0.045+0.005 
 KNM 0.09+0.01 
 ECONBHD 0.515+0.045 


1. 当遇上基本面投资法(上) “反向”战略非唱反调/冷眼 【冷眼专栏】漫漫投资路
2. Stocks on Radar - AirAsia Group (5099) AmInvest Research Reports
3. Stocks on Radar - Elsoft Research (0090) AmInvest Research Reports
4. FPI FY19 revenue growth expected to hit 15% FPI 2大因素前景看好台灣聯友今年再 尋突破
5. [转贴] 真实还原97亚洲金融风暴,韩国从暴富到破产仅用时7天! Good Articles to Share
6. JAKS Resources Berhad - RM25.5m P&L Hit PublicInvest Research
7. Fear on Bumi Armada is probably overdone - felicity Good Articles to Share
8. THE PERCEPTION OF P/E or: How I learned to fear my Wife the bursa journey that worked for me. 2000-2019
Partners & Brokers